Ritonavir

HIV-1 Infection

Ritonavir is primarily used as part of a combination therapy to treat human immunodeficiency virus (HIV-1) infection. It belongs to a class of drugs known as protease inhibitors. When used with other antiretroviral medications, it helps to:

• Decrease the amount of HIV in the blood (viral load).
• Increase the number of CD4 (T) cells, which help the immune system fight infections.
• Reduce the risk of complications related to HIV.

It is important to note that ritonavir does not cure HIV and may not prevent the spread of the virus to others.

COVID-19 Treatment

Ritonavir is also used in combination with another antiviral drug, nirmatrelvir, to treat mild-to-moderate COVID-19. This combination is typically prescribed for adults and children 12 years of age and older (weighing at least 40 kg) who have tested positive for the virus and are at a high risk for developing severe disease or requiring hospitalization.

Pharmacokinetic Enhancer

In many HIV treatment regimens, ritonavir is used at low doses as a booster. It works by slowing down the body's breakdown of other protease inhibitors, which allows those medications to stay in the blood at higher, more effective levels for longer periods.

Blocking Viral Replication

Ritonavir belongs to a class of drugs known as protease inhibitors. It works by interfering with an enzyme called protease, which certain viruses use to create new copies of themselves. By blocking this enzyme, the medication helps decrease the amount of the virus in the body and prevents it from spreading to healthy cells.

Enhancing Other Medications

Ritonavir is frequently used as a booster for other antiviral medications. It slows down the activity of specific enzymes in the liver that are responsible for breaking down drugs. By slowing this process, ritonavir allows other antiviral medications to remain in the body at higher concentrations for a longer duration.

This boosting effect helps the primary antiviral treatment work more effectively against infections like HIV or COVID-19. While ritonavir can fight viruses on its own, its role as a booster is often its primary function in modern treatment combinations, ensuring that other drugs reach the levels necessary to stop viral multiplication.

Common Side Effects

Many people taking ritonavir experience mild to moderate side effects. These often include:

• Nausea, vomiting, or diarrhea
• Stomach pain or loss of appetite
• Changes in the sense of taste, such as a metallic taste
• Tingling or numbness, especially around the mouth, hands, or feet
• Headache or dizziness
• Feeling unusually tired or weak
• Flushing or sweating

Serious Side Effects

While less common, ritonavir can cause serious health problems. Contact a healthcare provider immediately if you experience:

• Liver problems: Yellowing of the skin or eyes (jaundice), dark-colored urine, pale stools, or pain in the upper right side of the stomach.
• Pancreatitis: Severe pain in the upper stomach that may spread to the back, often accompanied by nausea and vomiting.
• Severe skin reactions: A rash that blisters or peels, which may be accompanied by fever or muscle aches.
• High blood sugar: Increased thirst, frequent urination, or blurred vision.
• Heart rhythm changes: Feeling like your heart is skipping beats, fluttering, or beating too fast.
• Allergic reactions: Swelling of the face, lips, or throat, or difficulty breathing.

Ritonavir may also cause changes in body fat distribution, such as increased fat in the upper back and neck or around the trunk, and loss of fat from the arms and legs.

Drug Interactions

Ritonavir is a potent inhibitor of certain liver enzymes. This means it can significantly increase the levels of many other medications in the blood, which may lead to serious or life-threatening adverse reactions. It is critical to disclose all medications, over-the-counter drugs, and herbal supplements to a healthcare provider before use.

Liver Toxicity

Cases of liver damage, including hepatitis and jaundice, have been reported. People with underlying liver diseases, such as Hepatitis B or Hepatitis C, are at a higher risk for liver complications. Healthcare providers usually perform blood tests to check liver function before starting and during treatment.

Pancreatitis

Inflammation of the pancreas (pancreatitis), which can be fatal, has occurred in patients taking ritonavir. This risk may be higher in those with significantly elevated triglyceride levels. Immediate medical evaluation is necessary if symptoms like severe abdominal pain, nausea, or vomiting develop.

Metabolic and Heart Concerns

• Blood Sugar: New-onset diabetes, worsening of existing diabetes, and high blood sugar (hyperglycemia) have been observed.
• Lipid Levels: Treatment can lead to large increases in the concentration of total cholesterol and triglycerides.
• Heart Rhythm: Ritonavir may cause changes in the heart's electrical rhythm, specifically PR interval prolongation, which can lead to heart block in some patients.

Immune and Physical Changes

Patients with HIV may experience immune reconstitution syndrome, where the immune system responds aggressively to previous or hidden infections. Changes in body fat distribution, such as increased fat in the trunk and neck or thinning of the limbs, may also occur during therapy.

Pregnancy

Ritonavir is frequently used during pregnancy as part of combination therapy for HIV. Available data from human studies have generally not shown an increased risk of major birth defects. However, clinical information is more limited when ritonavir is used for other conditions, such as COVID-19.

Individuals who are pregnant or planning to become pregnant should discuss their treatment options with a healthcare provider to weigh the benefits of the medication against potential risks.

Breastfeeding

The decision to breastfeed while taking ritonavir depends on the medical condition being treated and local health recommendations:

• HIV: In the United States, health experts recommend that individuals with HIV avoid breastfeeding to prevent the transmission of the virus to the infant through breast milk.
• General Safety: It is not known if ritonavir is present in human breast milk, although it has been detected in animal milk. Because of the potential for serious side effects in a nursing infant, a healthcare provider will help determine whether to stop breastfeeding or stop the medication based on the mother's medical needs.

Available Forms

Ritonavir is manufactured in several oral formats to accommodate different patient needs:

• Oral Tablets: These are film-coated tablets intended for oral administration.
• Oral Capsules: These are soft gelatin capsules that contain the medication in a liquid-filled form.
• Oral Solution: This is a liquid formulation of the medication.
• Oral Powder: This form is intended to be mixed with soft foods or liquids to create an oral suspension.

In certain combination therapies, ritonavir may be provided in co-packaged blister cards alongside other antiviral medications.

FDA Approval Status

Ritonavir was first approved by the U.S. Food and Drug Administration (FDA) in 1996. It is indicated for the treatment of HIV-1 infection in both adults and pediatric patients when used in combination with other antiretroviral medications. It belongs to a class of drugs known as protease inhibitors.

COVID-19 Regulatory Status

Ritonavir is co-packaged with nirmatrelvir for the treatment of mild-to-moderate COVID-19. This combination was initially granted Emergency Use Authorization (EUA) by the FDA in December 2021 for use in adults and certain pediatric patients at high risk for progression to severe disease. The FDA has since granted formal approval for this combination for use in specific high-risk adult populations.

Safety and Regulatory Requirements

The FDA classifies ritonavir as a prescription-only medication. While it does not currently have a Boxed Warning, the FDA-approved labeling includes extensive warnings regarding drug-drug interactions. Because ritonavir is a potent inhibitor of certain liver enzymes, it can significantly increase the levels of other medications in the blood, potentially leading to severe or life-threatening reactions. Healthcare providers are required to screen all concurrent medications before prescribing ritonavir.

The oral solution form of ritonavir contains a high concentration of alcohol, approximately 43% by volume. This high alcohol content is a primary concern for specific drug interactions and general safety.

Medication Interactions

Due to the alcohol content in the liquid formulation, ritonavir oral solution should not be used with certain other drugs. Taking it with disulfiram or metronidazole can cause a disulfiram-like reaction, which may include symptoms such as:

• Severe nausea and vomiting
• Abdominal cramps
• Headaches
• Flushing

Safety Considerations

The alcohol in ritonavir oral solution may cause side effects such as dizziness or drowsiness. Consuming additional alcohol while taking this medication may increase these effects or place extra stress on the liver. While ritonavir tablets do not contain the same high level of alcohol as the oral solution, it is still important to discuss alcohol consumption with a healthcare provider, especially for patients with a history of liver disease or those who must avoid alcohol for other medical reasons.